Parkinson's disease (PD) is characterized by widespread distribution of Lewy bodies, which are composed of phosphorylated and aggregated forms of alpha-Synuclein (alpha-Syn), in the brain. Although the accumulation and propagation of alpha-Syn contribute to the development of PD, the involvement of the blood-brain barrier (BBB) in these processes remains unknown. Pericytes, one of the cell types that constitute the BBB, degrade various forms of alpha-Syn. However, the detailed mechanisms involved in alpha-Syn degradation by pericytes remain poorly understood. Therefore, in this study, we aimed to determine the ability of the BBB-constituting cells, particularly primary cultures of rat pericytes, brain endothelial cells, and astrocytes, to degrade alpha-Syn. After alpha-Syn uptake by the cells, intracellular alpha-Syn decreased only in pericytes. This pericyte-specific alpha-Syn decrease was inhibited by an autophagy inhibitor, bafilomycin A1, and a proteasome inhibitor, MG132. siRNA-mediated knockdown of degradation enzymes or familial PD-associated genes, including cathepsin D, DJ-1, and LRRK2, did not affect alpha-Syn clearance in pericytes. However, pharmacological inhibitors of Akt, ERK, and p38 MAPK inhibited alpha-Syn degradation by pericytes. In conclusion, our results suggest that alpha-Syn degradation by pericytes is mediated by an autophagy-lysosome system and a ubiquitin-proteasome system via alpha-Syn-activated Akt, ERK, and p38 MAPK signaling pathways.